Email: cspc@cspc.cn
News
News Center
Aug. 03
2026
VOLUNTARY ANNOUNCEMENT - PHASE IB/II CLINICAL TRIAL OF SYS 6090 INJECTION FOR THE TREATMENT OF COLORECTAL CANCER OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHI
Jul. 31
VOLUNTARY ANNOUNCEMENT - RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS VACCINE (SYS6057) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYS6041 AS A COMBINATION THERAPY FOR THE TREATMENT OF RECURRENT OVARIAN CANCER OFFICIALLY INITIATED AT THE F
Jul. 29
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2062 INJECTION FOR THE TREATMENT OF ADULT ESSENTIAL HYPERTENSION OFFICIALLY INITIATED AT THE FIRST CENTRE
VOLUNTARY ANNOUNCEMENT - CRB-701 (SYS6002) RECEIVES U.S. FDA CLEARANCE FOR THE REGISTRATIONAL TRIAL FOR THE SECOND-LINE TREATMENT OF OROPHARYNGEAL CANCER
Jul. 27
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF AMMOXETINE HYDROCHLORIDE ENTERIC-COATED TABLETS (HA1406) FOR THE TREATMENT OF PATIENTS WITH DEPRESSION MET
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
